Company / Free Cash Flow
Sana Biotechnology, Inc. Free Cash Flow History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$256.6M
FY2024
5-year range
-$310.9M / -$161.9M
FY2020-FY2024
Trend
+6.2%
vs FY2023
Sector context
#161 of 194
Health Care
What the data says
Sana Biotechnology, Inc.'s free cash flow of -$257M is lower than 83% of companies in the Health Care sector (FY2024). Improved from -$311M to -$257M over the past 2 years.
Based on SEC 10-K filings.
-$257M in FY2024.
Improved from -$311M to -$257M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 194This company -$256.6M Sector average $470.6M
▼
-154.5% below sector average
Key checks
Key Insights
- In FY2024, free cash flow increased 6.2% year-over-year.
- Ranks #161 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2019.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$256.6M | +6.2% |
| FY2023 | -$273.6M | +12.0% |
| FY2022 | -$310.9M | -10.7% |
| FY2021 | -$280.9M | -73.6% |
| FY2020 | -$161.9M | -45.0% |
| FY2019 | -$111.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026